catalyx space | $5,400,000 | (Nov 4, 2025)
Zeeg | $1,265,935 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
NextPoint Therapeutics, Inc.
- 15/02/2024
- Series B
- $42,500,000
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
- Industry Biotechnology
- Website https://nextpointtx.com/
- LinkedIn https://www.linkedin.com/company/nextpoint-therapeutics/
Related People
Ivan CheungFounder
United States -
Scarsdale, New York
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
octonomy | $20,000,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)